$ETSY

Etsy upgraded, TJX downgraded: Wall Street's top analyst calls

Analysts upgraded Etsy (ETSY) to Buy with a $105 target, citing improved growth. Analog Devices (ADI) was upgraded by Seaport and Bernstein, with targets of $425 and $465, respectively, due to AI opportunities. Merck (MRK) was upgraded by Morgan Stanley to Overweight with a $179 target, but downgraded by RBC to Sector Perform with a $150 target. Progressive (PGR) was upgraded to Outperform with a $250 target, while Allstate (ALL) was downgraded to Underperform with a $250 target. TJX (TJX) was d

Original reporting
Published Aug 20, 2026, 1:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Etsy upgraded, TJX downgraded: Wall Street's top analyst calls — source image
Decision brief

The 30-second read

$ETSYBullishLow
01

Why it matters

Collective upgrades and downgrades provide a snapshot of shifting analyst sentiment, but each individual change is modest in scale.

02

Market read

Analyst rating shifts can trigger short‑term price moves, but the overall market impact is limited.

03

What to watch

Potential macro headwinds could dampen the impact of individual analyst actions.

Relevance 5/10Novelty 3/10Timing: today

Background

The article aggregates recent analyst rating changes and price target adjustments across multiple US‑listed companies.

Company-level read

Ticker impact

$ETSYBullishHigh confidence
Context

BofA upgraded Etsy to Buy with a $105 price target, citing management changes and growth improvement.

Expected impact

moderate upside if price approaches $105.

Evidence & confidence

Upgrade and higher target suggest near-term price appreciation.

$ADIBullishHigh confidence
Context

Seaport Research upgraded Analog Devices to Buy, raising the target to $425 on AI data‑center opportunity.

Expected impact

possible rally toward $425.

Evidence & confidence

Analyst upgrade with higher target indicates bullish outlook.

$MRKNeutralMedium confidence
Context

Morgan Stanley upgraded Merck to Overweight with a $179 target, while RBC later downgraded it to Sector Perform with a $150 target.

Expected impact

price may swing between $150‑$179.

Evidence & confidence

Conflicting analyst views could cause short‑term moves.

$PGRBullishMedium confidence
Context

Keefe Bruyette upgraded Progressive to Outperform with a $250 target, citing auto‑policy growth dynamics.

Expected impact

potential modest upside.

Evidence & confidence

Higher target reflects improved outlook.

$AMTBullishHigh confidence
Context

Barclays upgraded American Tower to Overweight with a $198 target, noting low valuations and catalyst potential.

Expected impact

upward pressure toward $198.

Evidence & confidence

Analyst view signals undervaluation.

$TJXBearishHigh confidence
Context

Citi downgraded TJX to Neutral and Gordon Haskett to Accumulate, cutting the target to $154‑$155 after a weak Q2.

Expected impact

downside risk toward $154.

Evidence & confidence

Lower target reflects weaker performance.

$ALLBearishMedium confidence
Context

Keefe Bruyette downgraded Allstate to Underperform with a $250 target, citing liability loss trends.

Expected impact

potential decline toward $250.

Evidence & confidence

Negative outlook on loss ratios.

$COTYBearishHigh confidence
Context

RBC Capital downgraded Coty to Sector Perform with a $3 target after mixed Q4 guidance.

Expected impact

downside pressure toward $3.

Evidence & confidence

Target reduction signals weak outlook.

Market effects

Broad analyst upgrades may lift sentiment in consumer discretionary and technology sectors.

US market focus; limited direct regional effect.

Minor, as changes are company‑specific.

Counterpoint

Some upgrades may be premature given broader market volatility.

Key entities

  • BofA

    Upgraded Etsy to Buy.

  • Seaport Research

    Upgraded Analog Devices to Buy.

  • Morgan Stanley

    Upgraded Merck to Overweight; resumed KDP coverage.

Related articles

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$WMTMed

Consumer Tech (Aug 17-21): Walmart & Alibaba Posts Earnings, Trump Targets U.S. Space Launch Growth & Mor

Walmart (WMT) reported earnings of $187.9B, beating estimates. Alibaba (BABA) reported $39.64B revenue, up 9% YoY, but missed earnings estimates. Amazon (AMZN) plans to expand Prime Air to 500 U.S. locations. PayPal (PYPL) is in talks for a potential buyout. NetEase (NTES) reported mixed Q2 results. Futu (FUTU) beat revenue estimates. Nokia (NOK) plans to cut most of its China workforce. Meta (META), Google (GOOG), and Snap (SNAP) won a legal reprieve. NVIDIA (NVDA) explores partnership with Reb

$MRNAHighAI 8/10

Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story

Moderna (MRNA) shares surged 129% week-on-week, peaking at $176.66, after reporting positive phase 3 trial results for its melanoma therapy candidate with Merck. The therapy met primary and key secondary endpoints, showing significant improvements in recurrence-free and distant metastasis-free survival. Both companies see potential in the large melanoma market, with 112,000 new US cases expected this year. Hedge funds increased holdings in Moderna, with 52 funds holding positions worth $1.4 bill

$TJXMedAI 8/10

Why TJX Stock Dropped Today

TJX Companies (TJX) reported Q2 earnings of $1.22 per share, beating estimates, with sales at $15.2 billion. Non-GAAP earnings rose 11%, while GAAP earnings surged 24% due to tariff refunds. Management expects slower growth in Q3 and full-year earnings of $5.33 per share. TJX stock initially dropped 6% but recovered to a 1.3% decline.

$AAPLMed

5 big analyst AI moves: Apple upgraded on foldable iPhone push, new AI strategy

Rothschild upgraded Apple to Buy, raising its price target to $400, citing a foldable iPhone launch and AI strategy shift. Wolfe Research remains bullish on AI semiconductor stocks, with Nvidia as its top pick. Bernstein upgraded Analog Devices to Outperform, citing strong results and guidance. Goldman reiterated MongoDB at Buy, expecting Atlas growth near 30%. Deutsche Bank downgraded SentinelOne to Hold after a strong rally.

$TJXMed

Jim Cramer Discussed Ross Stores, Inc. (NASDAQ:ROST) & TJX

Jim Cramer discussed the performance of TJX (NYSE:TJX) and Ross Stores (NASDAQ:ROST), noting their divergent share prices in 2026. TJX is down 8.9% YTD, while Ross Stores is up 30%. Cramer attributed Ross Stores' performance to its CEO, Jim Conroy. TJX reported Q2 earnings, with comparable same-store sales up 4% and raised full-year profit margin guidance to 11.2% and EPS to $4.09-$4.13. Ross Stores reported strong earnings, beating revenue and earnings estimates, with comparable store sales up